Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02056769
Other study ID # CT-PIPS
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date April 2014
Est. completion date February 2024

Study information

Verified date February 2023
Source Nova Scotia Health Authority
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with brain hemorrhage resulting from a ruptured aneurysm (SAH) are at risk of developing a condition called vasospasm, one or two weeks after their hemorrhage. This is a major cause of stroke and death following SAH. A special type of CT scan, called CT perfusion, analyzes regional blood flow in the brain. We hypothesize that CT perfusion scans performed on admission and day 6 post-hemorrhage will enable us to predict which patients will go on to develop vasospasm.


Description:

Rupture of a brain aneurysm results in a type of bleeding into the brain called subarachnoid hemorrhage (SAH). This is a substantial cause of morbidity and mortality world-wide: even with the best possible care, up to half of patients die and many are left disabled. Sometimes this is because the immediate brain damage from the bleed is very severe. However, many patients who seem to be doing well at first go on to develop something called "vasospasm": narrowing of large arteries in the brain. This results in the brain not getting enough blood, and the patient can suffer a stroke as a result. The lack of blood to the brain is called delayed cerebral ischemia (DCI), and is the major secondary cause of stroke and death in patients who survived the initial aneurysm rupture. Vasospasm can be seen on angiograms (blood vessel imaging) in about two-thirds of SAH patients, and causes neurological symptoms of DCI in half of those patients. It usually develops about a week or so after SAH. Early diagnosis and treatment of cerebral vasospasm and delayed cerebral ischemia (DCI) reduces morbidity and mortality in SAH patients. CT perfusion imaging is able to identify areas of reduced cerebral blood flow that are at risk of DCI and stroke. This technique is able to measure cerebral blood flow and blood volume (CBF, CBV), and calculates two other measures of cerebral perfusion: time to peak intensity (TTP) and mean transit time (MTT). Taken together, these provide information about the amount of blood the brain is receiving and whether the brain is compensating for any reduction in flow. This is helpful because seeing vasospasm on imaging is not enough to predict brain ischemia and stroke; the additional physiological information provided by the perfusion assessment strengthens the diagnosis of DCI. Early evidence suggests that CT perfusion is a fast, accurate, inexpensive and non-invasive method of brain imaging to identify patients with DCI after SAH, and guide appropriate therapy. If we were able to successfully predict which patients are at high risk of DCI and/or stroke, we could intervene early. This could improve patient outcomes, while potentially allowing better use of limited intensive care and nursing resources. Other studies have shown that patients with DCI had altered perfusion prior to developing clinical symptoms, but we do not know whether we can use CT perfusion to predict patients at risk, or which CT perfusion measurements (e.g., CBF or TTP) are most useful. The radiation risk associated with CT perfusion imaging is negligible, due to advances in CT technology which allow for routine simultaneous CT perfusion and CT angiogram (CTA) without a significant increase in radiation dose over conventional head CT-CTA alone. Judicious use of CT perfusion, through a structured algorithm that includes routine perfusion scans at admission and during the peak risk period for vasospasm, may actually decrease cumulative radiation dose for patients with SAH, by ruling out perfusion deficit and brain ischemia as a cause of decreased neurological function and limiting repeated angiograms.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 41
Est. completion date February 2024
Est. primary completion date June 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patient is between 18 and 75 years of age (inclusive). - Patient has a documented aneurysmal SAH. - Patient or next of kin or person with appropriate power of attorney has provided written informed consent. - Patient is willing and available for study follow-up visits. - Patient has not been previously entered into this study. Exclusion Criteria: - Inability to obtain informed written consent. - Patient is < 18 or > 75 years old. - Patient is not expected to survive >24 hours (e.g. those presenting with loss of brain stem reflexes, or patients transferred to the Halifax Infirmary ICU for consideration of organ donation rather than active treatment) - Patient history indicates high risk of non-compliance (e.g., substance abuse, psychosocial issues, etc.) - Patient is currently breast feeding, or pregnant - Patient is currently enrolled in another clinical study (device or drug).

Study Design


Intervention

Radiation:
CT Perfusion
Quantitative CT Perfusion imaging

Locations

Country Name City State
Canada Halifax Infirmary, Capital District Health Authority Halifax Nova Scotia

Sponsors (1)

Lead Sponsor Collaborator
Nova Scotia Health Authority

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Delayed Cerebral Ischemia Delayed cerebral ischemia is defined using a consensus recently agreed upon by an international panel of experts: namely, 1) stroke seen on CT or MRI scan, or proven at autopsy (not including stroke related to the aneurysm treatment), or 2) clinical deterioration presumed to be caused by DCI after other causes are excluded. 30 days post-SAH
Primary CBF Admit Cerebral blood flow as measured on CT perfusion study on admission Baseline
Primary CBV Admit Cerebral blood volume as measured on CT perfusion study on admission Baseline
Primary MTT Admit Mean transit time as measured on CT perfusion study on admission Baseline
Primary TTP Admit Time to peak as measured on CT perfusion study on admission Baseline
Primary CBF day 6 Cerebral blood flow as measured on CT perfusion study on day 6 following subarachnoid hemorrhage Day 6 post-SAH
Primary CBV day 6 Cerebral blood volume as measured on CT perfusion study on day 6 following subarachnoid hemorrhage Day 6 post-SAH
Primary MTT day 6 Mean transit time as measured on CT perfusion study on day 6 following subarachnoid hemorrhage Day 6 post-SAH
Primary TTP day 6 Time to peak as measured on CT perfusion study on day 6 following subarachnoid hemorrhage Day 6 post-SAH
Secondary Radiation Dose Total cumulative radiation dose from cranial imaging (CT Head, CT angiogram, CT perfusion, catheter angiography, endovascular coiling) during the initial hospital admission for SAH, up to 30 days post-SAH. 30 days post-SAH
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06043167 - Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
Recruiting NCT04189471 - Recovery After Cerebral Hemorrhage
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Completed NCT05131295 - Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage. Phase 3
Recruiting NCT02962349 - TRansfusion Strategies in Acute Brain INjured Patients N/A
Completed NCT02872857 - Subarachnoid Hemorrhage Recovery And Galantamine Phase 1/Phase 2
Terminated NCT02216513 - Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage Phase 0
Completed NCT03164434 - Influence of Drainage on EVD ICP-signal
Not yet recruiting NCT00905931 - Lycopene Following Aneurysmal Subarachnoid Haemorrhage Phase 2
Completed NCT02389634 - Identification of Novel Molecular Markers for Vasospasm
Completed NCT01077206 - High-dose Simvastatin for Aneurysmal Subarachnoid Haemorrhage Phase 2/Phase 3
Completed NCT00962546 - Computed Tomographic (CT) Perfusion and CT Angiography as Screening Tools for Vasospasm Following Subarachnoid Hemorrhage N/A
Completed NCT01261091 - Early Tracheostomy in Ventilated Stroke Patients N/A
Completed NCT00507104 - Pituitary Functions After Traumatic Brain Injury (TBI) and/or Subarachnoid Hemorrhage (SAH)
Completed NCT00071565 - Familial Intracranial Aneurysm Study II N/A
Recruiting NCT05113381 - The Purpose of This Study is to Determine Whether CerebroFlo™ EVD Catheter is Effective During the Treatment of IVH N/A
Completed NCT04052646 - Prehospital Deaths From Spontaneous Subarachnoid Haemorrhages
Recruiting NCT04548596 - NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
Recruiting NCT06033378 - Blood Pressure Treatment in ICU Patients With Subarachniodal Haemorrhage. N/A
Completed NCT04308577 - Diet Induced Ketosis for Brain Injury - A Feasibility Study N/A